Lymphovascular invasion have a similar prognostic value as lymph node involvement in patients undergoing radical cystectomy with urothelial carcinoma

被引:9
作者
Yuk, Hyeong Dong [1 ]
Jeong, Chang Wook [2 ]
Kwak, Cheol [2 ]
Kim, Hyeon Hoe [2 ]
Ku, Ja Hyeon [2 ]
机构
[1] Inje Univ, Sanggye Paik Hosp, Dept Urol, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Urol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
BLADDER-CANCER; PERINEURAL INVASION; RISK-FACTORS; METASTASIS; VALIDATION; RECURRENCE; SURVIVAL;
D O I
10.1038/s41598-018-34299-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To determine the prognostic value of lymphovascular invasion (LVI) in patients with bladder cancer who underwent radical cystectomy. Total of 747 patients underwent radical cystectomy; of these, only 164 did not undergo lymph node dissection (LND). The patients were divided into 4 groups: NO, N1, LVI without LND, and non-LVI without LND. Patients in the N1 and LVI groups had significantly higher T stages and grades, as well 1.5- to 2-fold higher recurrence and mortality rates. Overall survival (OS) was significantly poorer in the N1 group, compared with the NO and non-LVI groups (p = 0.001 and 0.012), and in the LVI group relative to the NO and non-LVI groups (p = < 0.001 and <0.001). Recurrence-free survival (RFS) was also significantly poorer in the N1 group relative to the NO and non-LVI groups (p = < 0.001 and <0.001), and in the LVI group relative to the NO and non-LVI groups (p = < 0.001 and <0.001). Among patients undergoing radical cystectomy, the clinical results predicted by LVI were similar to those predicted by lymph node involvement. Therefore, the role of adjuvant chemotherapy or immunotherapy may need to be prospectively evaluated in LVI-positive patients regardless of T stage after radical cystectomy.
引用
收藏
页数:6
相关论文
共 24 条
[1]   Nodal involvement in bladder cancer cases treated with radical cystectomy: Incidence and prognosis [J].
Abdel-Latif, M ;
Abol-Enein, H ;
El-Baz, M ;
Ghoneim, MA .
JOURNAL OF UROLOGY, 2004, 172 (01) :85-89
[2]   Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial [J].
Albers, P ;
Siener, R ;
Kliesch, S ;
Weissbach, L ;
Krege, S ;
Sparwasser, C ;
Schulze, H ;
Heidenreich, A ;
de Riese, W ;
Loy, V ;
Bierhoff, E ;
Wittekind, C ;
Fimmers, R ;
Hartmann, M .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1505-1512
[3]   Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry [J].
Alexander-Sefre, F ;
Singh, N ;
Ayhan, A ;
Salveson, HB ;
Wilbanks, G ;
Jacobs, IJ .
JOURNAL OF CLINICAL PATHOLOGY, 2003, 56 (10) :786-788
[4]  
Alitalo Kari, 2004, Cancer Res, V64, P9225, DOI 10.1158/0008-5472.CAN-04-2475
[5]   Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Bohle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61 [J].
Babjuk, Marko ;
Burger, Maximilian ;
Comperat, Eva ;
Palou, Joan ;
Roupret, Morgan ;
van Rhijn, Bas ;
Shariat, Shahrokh ;
Sylvester, Richard ;
Zigeuner, Richard ;
Gontero, Paolo ;
Mostafid, Hugh .
EUROPEAN UROLOGY, 2017, 71 (06) :E173-E174
[6]   Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort [J].
Bassi, P ;
Ferrante, GD ;
Piazza, N ;
Spinadin, R ;
Carando, R ;
Pappagallo, G ;
Pagano, F .
JOURNAL OF UROLOGY, 1999, 161 (05) :1494-1497
[7]   Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial [J].
Bolenz, Christian ;
Herrmann, Edwin ;
Bastian, Patrick J. ;
Michel, Maurice S. ;
Wuelfing, Christian ;
Tiemann, Arne ;
Buchner, Alexander ;
Stief, Christian G. ;
Fritsche, Hans-Martin ;
Burger, Maximilian ;
Wieland, Wolf F. ;
Hoefner, Thomas ;
Haferkamp, Axel ;
Hohenfellner, Markus ;
Mueller, Stefan C. ;
Stroebel, Philipp ;
Trojan, Lutz .
BJU INTERNATIONAL, 2010, 106 (04) :493-498
[8]   Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data [J].
Bono, AV ;
Goebell, PJ ;
Groshen, S ;
Lehmann, J ;
Studer, U ;
Torti, FM ;
Abol-Enein, H ;
Bassi, P ;
Boyer, M ;
Coppin, CML ;
Cortesi, E ;
Hall, RR ;
Horwich, A ;
Malmström, PU ;
Martínez-Piñeiro, JA ;
Sengelov, L ;
Sherif, A ;
Wallace, DMA ;
Clarke, NW ;
Roberts, JT ;
Sylvester, R ;
Parmar, MKB ;
Stewart, LA ;
Tierney, JF ;
Vale, CL .
EUROPEAN UROLOGY, 2005, 48 (02) :189-201
[9]   Epidemiology and Risk Factors of Urothelial Bladder Cancer [J].
Burger, Maximilian ;
Catto, James W. F. ;
Dalbagni, Guido ;
Grossman, H. Barton ;
Herr, Harry ;
Karakiewicz, Pierre ;
Kassouf, Wassim ;
Kiemeney, Lambertus A. ;
La Vecchia, Carlo ;
Shariat, Shahrokh ;
Lotan, Yair .
EUROPEAN UROLOGY, 2013, 63 (02) :234-241
[10]   Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy [J].
Gondo, Tatsuo ;
Nakashima, Jun ;
Ozu, Choichiro ;
Ohno, Yoshio ;
Horiguchi, Yutaka ;
Namiki, Kazunori ;
Yoshioka, Kunihiko ;
Ohori, Makoto ;
Hatano, Tadashi ;
Tachibana, Masaaki .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (05) :456-461